Morgan Stanley Compass Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 248,749 shares of CMPX stock, worth $855,696. This represents 0.0% of its overall portfolio holdings.

Number of Shares

248,749

Previous 839,176 70.36%

Holding current value

$855,696

Previous $1.59 Million 59.47%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$1.46 - $2.69 $862,023 - $1.59 Million	-590,427 Reduced 70.36%	248,749 $646,000
Q1 2025 May 15, 2025	BUY	$1.4 - $3.9 $644,873 - $1.8 Million	460,624 Added 121.68%	839,176 $1.59 Million
Q4 2024 Feb 14, 2025	BUY	$1.35 - $1.98 $897 - $1,316	665 Added 0.18%	378,552 $548,000
Q3 2024 May 14, 2025	BUY	$0.8 - $1.88 $167,976 - $394,745	209,971 Added 125.05%	377,887 $695,000
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.88 $167,976 - $394,745	209,971 Added 125.05%	377,887 $695,000
Q2 2024 May 14, 2025	SELL	$1.0 - $1.85 $210,636 - $389,676	-210,636 Reduced 55.64%	167,916 $167,000
Q2 2024 Oct 17, 2024	BUY	$1.0 - $1.85 $3,685 - $6,817	3,685 Added 2.24%	167,916 $167,000
Q2 2024 Aug 14, 2024	BUY	$1.0 - $1.85 $3,685 - $6,817	3,685 Added 2.24%	167,916 $167,000
Q1 2024 Oct 17, 2024	SELL	$1.2 - $2.29 $4,422 - $8,438	-3,685 Reduced 2.19%	164,231 $325,000
Q1 2024 Aug 16, 2024	SELL	$1.2 - $2.29 $76,510 - $146,008	-63,759 Reduced 27.97%	164,231 $325,000
Q1 2024 May 15, 2024	SELL	$1.2 - $2.29 $76,510 - $146,008	-63,759 Reduced 27.97%	164,231 $325,000
Q4 2023 Aug 16, 2024	BUY	$1.4 - $1.98 $84,103 - $118,946	60,074 Added 35.78%	227,990 $355,000
Q4 2023 Feb 13, 2024	BUY	$1.4 - $1.98 $230,581 - $326,107	164,701 Added 260.24%	227,990 $355,000
Q3 2023 Nov 15, 2023	SELL	$1.87 - $3.25 $103,985 - $180,722	-55,607 Reduced 46.77%	63,289 $124,000
Q2 2023 Aug 14, 2023	SELL	$2.64 - $3.48 $108,683 - $143,264	-41,168 Reduced 25.72%	118,896 $378,000
Q1 2023 May 15, 2023	BUY	$3.14 - $5.48 $300,077 - $523,701	95,566 Added 148.17%	160,064 $523,000
Q4 2022 Feb 14, 2023	BUY	$2.55 - $5.41 $141,846 - $300,936	55,626 Added 626.98%	64,498 $324,000
Q3 2022 Nov 14, 2022	BUY	$1.9 - $3.37 $15,692 - $27,832	8,259 Added 1347.31%	8,872 $20,000
Q2 2022 Oct 27, 2022	SELL	$1.43 - $3.1 $37,700 - $81,728	-26,364 Reduced 97.73%	613 $2,000
Q2 2022 Aug 15, 2022	SELL	$1.43 - $3.1 $37,700 - $81,728	-26,364 Reduced 97.73%	613 $2,000
Q1 2022 Oct 27, 2022	BUY	$1.25 - $3.5 $32,955 - $92,274	26,364 Added 4300.82%	26,977 $37,000
Q1 2022 May 13, 2022	BUY	$1.25 - $3.5 $11,880 - $33,264	9,504 Added 54.39%	26,977 $37,000
Q4 2021 Feb 14, 2022	BUY	$2.88 - $3.98 $50,322 - $69,542	17,473 New	17,473 $56,000

Others Institutions Holding CMPX

# of Institutions

103

Shares Held

101M

Call Options Held

18.2K

Put Options Held

2.51M

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $348M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account